Join
Live feed
·
PRReleasevia Quantisnow
Allakos Inc. logo

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

ByQuantisnow·Wall Street's wire, on your screen.
ALLK· Allakos Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLK (Allakos Inc.) and more on Quantisnow.